Larvol Delta - Costeffectiveness-analysis-of-elranatamab-versus-physician39s-choice-of-treatment-nonBCMAdirected-regimens-in-patients-with-triple-class-exposed-multiple-myeloma-in-Japan

cimlanod (BMS986231) - BMS

http://www.ncbi.nlm.nih.gov/pubmed/42711198

Sebastian A Suarez

Sep 9, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next